Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Parmenter

Podiatrist Linton, IN Doctor of Podiatric Medicine

NPI 1013902089 CMS profile 182520

1206 N 1000 W Ste B, Linton, IN 47441

Open in the dashboard

General payments

$2,909

82 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Parmenter of Linton, IN is reported in the CMS Open Payments database as having received $2,909 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $133 6
2024 General $1 1
2023 General $325 6
2022 General $1,267 13
2021 General $47 3
2020 General $529 10
2019 General $606 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Parmenter
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Matthew Parmenter were reported at $133. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Matthew Parmenter Podiatrist median Middle half National median
2019 $606 $196 $72–$601 $163
2020 $529 $118 $38–$335 $114
2021 $47 $169 $57–$573 $132
2022 $1,267 $220 $74–$782 $149
2023 $325 $208 $71–$635 $160
2024 $1 $237 $87–$681 $164
2025 $133 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $1,414 12 payments
  2. Cook Medical LLC $402 2 payments
  3. Pfizer Inc. $146 14 payments
  4. Smith+Nephew, Inc. $143 8 payments
  5. Kerecis Limited $101 4 payments
  6. Allergan Inc. $91 6 payments
  7. Tactile Systems Technology Inc $67 5 payments
  8. Heron Therapeutics, Inc. $62 1 payment
  9. Medline Industries, Inc. $54 3 payments
  10. Orthofix Medical, Inc. $47 3 payments
  11. Other $381 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,586 78 payments
  2. Travel and Lodging $911 2 payments
  3. Consulting Fee $400 1 payment
  4. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. PROSTEP $1,050 3 payments
  2. ORTHOLOC 3DI $158 1 payment
  3. EUCRISA $111 11 payments
  4. DALVANCE $91 6 payments
  5. AUGMENT INJECTABLE $87 3 payments
  6. Kerecis Omega3 SurgiClose Wound Care $77 2 payments
  7. Kerecis Omega3 GraftGuide $76 1 payment
  8. Kerecis Omega3 SurgiClose Wound Care $76 1 payment
  9. Kerecis Omega3 Marigen $76 1 payment
  10. Kerecis Omega3 SurgiClose Wound Care $76 1 payment
  11. Other $1,401 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

722

Median for Podiatry: 160

Drug cost

$13,625

Median for Podiatry: $2,368

Branded share of claims

8%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 11 $6,166
Ketoconazole Generic 96 $2,098
Mupirocin Generic 119 $867
Gabapentin Generic 62 $740
Cefdinir Generic 45 $700
Triamcinolone Acetonide Generic 107 $572
Gentamicin Sulfate Generic 18 $500
Ampicillin Trihydrate Generic 15 $359
Doxycycline Hyclate Generic 29 $271
Minocycline Hcl Generic 15 $229

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$91,985

Of which drugs: $134

Medicare patients

532

Average age 74

Services billed

2,278

311 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Diabetes 41%
Ischemic heart disease 29%
Chronic kidney disease 22%
Atrial fibrillation 18%
Depression 18%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 24 1,000 $103

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record